Davy Guillarme previews his presentation at HPLC 2019 highlighting the new trends in LC×LC applied for biopharmaceutical characterization, including the hyphenation with high‑resolution mass spectrometry (HRMS) and ion mobility spectrometry (IMS).
At the previous HPLC 2018 symposium, there was a strong focus on the analytical characterization of protein biopharmaceuticals, including monoclonal antibodies (mAbs) and antibody–drug conjugates (ADCs). In particular, there was an opening plenary lecture from Stacey Ma (Genentech, San Francisco, California, USA) about the most recent analytical technologies used in the biopharmaceutical industry. Additionally, there were also several dedicated lectures and posters sessions on the analysis of mAbs, ADCs, and other formats of proteinâbased drugs.
Since the development of recombinant insulin in 1982, the number of proteinâbased drugs has dramatically increased, and protein biopharmaceuticals have emerged as important therapeutic options for the treatment of cancer, inflammatory and autoimmune disorders, Alzheimer’s disease, and even migraines. Based on this broad range of applications, numerous pharmaceutical companies are increasing their efforts aimed at the research and product development of biologics. Given their obvious benefits in terms of safety and efficacy, mAbs are today the most successful biopharmaceutical products and have totally reshaped the pharmaceutical market (1). As well as mAbs, there is also strong interest in mAb-related products, such as new ADC formats, fusion proteins, PEGylated proteins, bispecific antibodies (BsAbs), antibody fragments (nanobodies and Fab), and polyclonal antibodies (pAb). Last, but not least, some of the first-generation mAbs and fusion proteins will come off patent soon, and there is consequently a significant increase of biosimilars activity requiring powerful analytical methods for comparability assessment of originators and biosimilars.
It is indeed important to keep in mind that these products are highly complex in terms of structure, and the characterization of therapeutic mAbs and ADCs is a tremendous challenge to stateâofâthe-art analytical technologies. Indeed, subtle changes in these large (greater than 150 kDa) molecules can have profound effects on efficacy, pharmacokinetic properties, and toxicity. It is therefore important to have the ability to rapidly and accurately assess changes in the distribution of different isoforms, for example, glycosylation, oxidation, deamidation, lysine truncation of these biomolecules (2).
Today, the most widely used analytical approaches for therapeutic protein characterization are liquid chromatography (LC) and mass spectrometry (MS), probably as a result of the remarkable developments of these strategies in the past few years, which have enabled a new level of performance. Lectures and posters at HPLC 2019 will demonstrate the usefulness of modern LC and MS approaches to demonstrate the product quality and increase the safety of biopharmaceutical products.
As well as the conventional LC modes, such as size-exclusion chromatography (SEC), ion exchange chromatography (IEC), hydrophobic interaction chromatography (HIC), reversedâphase LC, and hydrophilic interaction liquid chromatography (HILIC), it is also possible to combine the most promising chromatographic strategies in a comprehensive two-dimensional liquid chromatography (LC×LC) setup. This allows for a more detailed characterization of some highly complex and heterogeneous new biological entities, thanks to a significantly better peak capacity. In addition, LC×LC also offers the opportunity to combine nondenaturing chromatographic modes requiring significant amount of nonvolatile salts (IEC and SEC) to MS, using a desalting step in the second dimension. Even though LC×LC is becoming more and more popular for the analysis of small molecules, it has only very recently been used for biopharmaceutical characterization (3,4).
During my presentation at the next HPLC 2019 symposium, I will try to highlight the new trends in LC×LC applied for biopharmaceutical characterization, including the hyphenation with highâresolution mass spectrometry (HRMS) and ion mobility spectrometry (IMS).
References
Davy Guillarme holds a Ph.D. degree in analytical chemistry from the University of Lyon, France. He is now senior lecturer at the University of Geneva in Switzerland. He has authored more than 200 journal articles related to pharmaceutical analysis. His expertise includes HPLC, UHPLC, HILIC, LC−MS, SFC, and the analysis of proteins and mAbs. He is an associate editor of Journal of Chromatography B and editorial advisory board member of several journals.
Katelynn Perrault Uptmor Receives the 2025 LCGC Emerging Leader in Chromatography Award
November 13th 2024November 2025 – LCGC International magazine has named Katelynn A. Perrault Uptmor, Assistant Professor of Chemistry at the College of William & Mary, the recipient of the 2025 Emerging Leader in Chromatography Award. This accolade, which highlights exceptional achievements by early-career scientists, celebrates Perrault Uptmor’s pioneering work in chromatography, particularly in the fields of forensic science, odor analysis, and complex volatile organic compounds (VOCs) research.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
LC–MS/MS Quantification of Plasma Proteins in Elephant Seals to Advance Wildlife Conservation
November 12th 2024Liquid chromatography and tandem mass spectrometry (LC–MS/MS) was used to show that repeated stress can cause delayed but sustained changes in blood plasma proteins associated with water conservation, immune responses, fat metabolism, insulin sensitivity, iron recycling, and hormone transport in elephant seals. Some of these changes may be novel markers of recent and chronic stress exposure in marine mammals.